Table 1.

Baseline demographic details and tumor characteristics of patients treated with adjuvant Hyperthermic Intra-VEsical Chemotherapy with mitomycin and intravesical Bacillus Calmette–Guerin (Moscow I strain) for nonmuscle invasive bladder cancer

	HIVEC (n=22)	BCG (n=29)	P
Age (median, range)	62 (4382)	61 (3880)	0.419
Gender (n, %)
Male	20 (91)	25 (86)	0.476
Female	2 (9)	4 (14)
T-stage (n, %)
Ta	10 (45.5)	10 (34.50	0.315
T1	8 (36.4)	14 (48.3)
T1+CIS	3 (13.6)	2 (6.9)
Ta+CIS	1 (4.5)	0 (0)
CIS only	0 (0)	3 (10.3)
Tumor grade (n, %)
Low grade	12 (54.5)	16 (55.2)	0.964
High grade	10 (45.5)	13 (44.8)
Single or multiple tumors
Single	11 (50)	16 (55)	0.591
Multiple (≥2)	11 (50)	13 (45)
Risk group (EORTC)
Intermediate risk	12 (54.5)	17 (58.6)	0.784
High risk	10 (45.5)	12 (41.4)

HIVEC: Hyperthermic Intra-VEsical Chemotherapy, BCG: Bacillus Calmette-Guerin, EORTC: European Organization for Research and Treatment of Cancer